Lilly Unveils TuneLab: AI-Driven Drug Discovery Platform with $1 Billion Research Investment
Summary
Eli Lilly unveils TuneLab, an AI-driven drug discovery platform backed by a $1 billion research investment, offering biotech companies access to AI models built on Lilly's extensive drug data and joining Lilly Catalyze360's offerings for biotech partners.
Key Points
- Lilly launches TuneLab platform to provide biotech companies access to AI-enabled drug discovery models built through over $1 billion in research investment
- TuneLab is powered by Lilly's drug disposition, safety, and preclinical datasets representing hundreds of thousands of unique molecules
- TuneLab is the newest addition to Lilly Catalyze360's offerings for biotech partners, which include strategic capital, laboratory facilities, and drug development expertise